- Gilead Sciences is accelerating its efforts to test a potential treatment for COVID-19, the disease caused by the growing coronavirus outbreak. The company just announced plans for two late-stage clinical studies.
- The California biotech will enroll approximately 1,000 patients with confirmed cases of COVID-19 across Asian countries and other areas with high rates of cases, the company stated Wednesday.
- The two trials will test an antiviral medication called remdesivir, a therapy that has been previously tested against the Ebola virus. The late-stage trials are primarily focused on assessing the drug’s efficacy, rather than just safety.
- Other studies of remdesivir are ongoing in China. A Gilead executive said these additional trials will „give us a more expansive breadth of data globally on the drug’s profile in a short amount of time.“
- Visit Business Insider’s homepage for more stories.
The $95 billion biotech Gilead Sciences is accelerating its effort to test a promising potential drug to treat COVID-19, the disease caused by the spreading coronavirus outbreak.
Gilead announced Wednesday plans for two late-stage clinical trials. The studies will assess different doses and treatment courses of the experimental antiviral medication, remdesivir, in about 1,000 patients with COVID-19.
The efforts build on other ongoing tests of the drug in China and the US. Gilead said these new studies will start enrolling patients in March „across Asian countries, as well as other countries globally with high numbers of diagnosed cases.“
Gilead said we’re likely to get the first results from some of those earlier studies in April.
The National Institutes of Health’s infectious disease unit recently started a trial of remdesivir in the US with COVID-19 patients.
„Gilead’s primary focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19, and this complementary array of studies helps to give us a more expansive breadth of data globally on the drug’s profile in a short amount of time,“ said Merdad Parsey, Gilead’s chief medical officer, in a statement.
Health officials and experts have emphasized the potential for remdesivir. A single case reported in The New England Journal of Medicine has stirred initial excitement about the drug’s potential.
„There is only one drug right now that we think may have real efficacy and that’s remdesivir,“ Bruce Aylward, an assistant director-general of the World Health Organization, said at a recent press conference, CNN reported.
- Read more:
- The US is gearing up to test the first coronavirus treatments and vaccines. Here’s how 6 top drugmakers are racing to tackle an outbreak that’s spreading around the world.
- Buzzy biotech Moderna is ‚looking at all options‘ to ramp up production just days after shipping the first potential coronavirus vaccine
- A vaccine for Wuhan coronavirus could take years to develop, based on our experience trying to fight Zika and Ebola
- Pharma giant Sanofi is developing a vaccine to fight the deadly coronavirus outbreak using its previous research on SARS
- „Wir befinden uns am Beginn einer Corona-Epidemie in Deutschland“, warnt Gesundheitsminister Spahn
- Die Tupper-Party ist vorbei: Das Kult-Unternehmen eurer Kindheit steckt tief in der Krise
- Übertragung, Symptome, Therapie — Experten beantworten die wichtigsten Fragen zum Coronavirus
- Netto druckt „unsichtbaren Barcode“ auf seine Produkte — und will so ein schwieriges Problem lösen
- Ist Sterbehilfe jetzt generell erlaubt? Was das Urteil für Schwerkranke, Angehörige und Ärzte bedeutet